spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Prostate-Specific Antigen 

 HSMN NewsFeed - 22 Mar 2024
Astellas Receives Positive CHMP Opinion for XTANDI(TM) in Additional Recurrent Early Prostate Cancer Treatment Setting
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2020
XTANDI(R) (enzalutamide soft capsules) Approved by China NMPA for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Apr 2019
U.S. FDA Accepts New Drug Application and Grants Priority Review for Darolutamide
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2017
Janssen Submits New Drug Application to U.S. FDA for Apalutamide (ARN-509) to Treat Men with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Sep 2017
Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (enzalutamide) in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 May 2016
Decipher Prostate Cancer Test Guides Timing of Postoperative Radiotherapy
Diagnostics Devices Oncology
 HSMN NewsFeed - 10 Mar 2016
ProMark(R) Prostate Cancer Prognostic Now Included in NCCN Guidelines
Diagnostics Oncology
 HSMN NewsFeed - 12 Oct 2015
Teva Announces Exclusive Launch of Generic Avodart(R) Capsules in the United States
Biopharmaceuticals Urology Generics Product Launch
 HSMN NewsFeed - 4 Mar 2015
Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC(R), a Prostate-Specific Antigen-Targeting Cancer Immunotherapy
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 29 Jul 2014
Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer
Biopharmaceuticals Diagnostics Oncology Licensing
 HSMN NewsFeed - 12 Jun 2014
Clarus Therapeutics Secures $31.5 Million in Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 15 May 2013
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 29 Oct 2012
Elekta’s Growth Through Innovation to Increase Use of Radiation Therapy and Improve Lives of Cancer Patients
Devices Oncology
 HSMN NewsFeed - 31 Aug 2012
Sophiris' Drug for Benign Prostatic Hyperplasia was Well Tolerated Using the Preferred Transrectal Route of Administration
Biopharmaceuticals Urology
 HSMN NewsFeed - 6 Mar 2012
Aragon Pharmaceuticals Secures $42 Million in Series C Financing to Advance Pipeline of Therapies Targeting Hormone-Driven Cancers
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 15 Feb 2012
FDA Approves Gen-Probe's PROGENSA(R) PCA3 Assay, First Urine-Based Molecular Test to Help Determine Need for Repeat Prostate Biopsies
Diagnostics FDA
 HSMN NewsFeed - 14 Oct 2011
Health Discovery Corporation Agrees with the U.S. Preventive Services Task Force’s Position Against PSA-Based Screening for Prostate Cancer and Believes Its Four-Gene Assay for Prostate Cancer is the Best Alternative to PSA
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 20 Sep 2011
Tokai Pharmaceuticals Raises $23 Million in Funding
Biopharmaceuticals Personnel Venture Capital
 HSMN NewsFeed - 6 Jun 2011
Bayer's Investigational Compound Radium-223 Chloride Met its Primary Endpoint of Significantly Improving Overall Survival in a Phase III Trial in Patients with Castration-Resistant Prostate Cancer That Has Spread to the Bone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Oct 2010
Phase III Data Showing Improved Survival With Jevtana(R) (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2010
Bayer Presents Clinical Data on Alpharadin in Metastatic Castration-Resistant Prostate Cancer (CRPC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2010
Genentech Provides Update on Phase III Study of Avastin in Men With Late Stage Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Mar 2010
AUA Responds to American Cancer Society Guideline for the Early Detection of Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 4 Dec 2009
Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Sep 2009
GENova Biotherapeutics prepares a 510(k) submission to the FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Aug 2009
Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Mar 2009
Ferring Pharmaceuticals Announces Immediate Availability of Degarelix for the Treatment of Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2008
FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 13 May 2008
EDAP Adds Premiere M.D. Anderson Cancer Center for Phase II/III Ablatherm-HIFU Clinical Trial
Devices Oncology
 HSMN NewsFeed - 30 Apr 2008
FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA
Biopharmaceuticals Devices Drug Delivery Oncology FDA
 HSMN NewsFeed - 3 Dec 2007
Immunicon Corporation Announced the Filing for FDA Clearance of the CellSearch(TM) Circulating Tumor Cell Kit for Monitoring Patients with Metastatic Androgen-Independent Prostate Cancer
Diagnostics Oncology
 HSMN NewsFeed - 4 Sep 2007
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Biopharmaceuticals Urology
 HSMN NewsFeed - 4 Jun 2007
Updated Study Results Reinforce Survival Benefit of Taxotere(R) (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2007
Panacea Pharmaceuticals Announces the Availability of PC Detect(sm) for Prostate Cancer Screening
Diagnostics Oncology
 HSMN NewsFeed - 22 May 2007
Outcomes Data Continue to Demonstrate Value of Cytogen's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2007
Seven-Year Survival Data Demonstrate use of Cytogen's PROSTASCINT(R) Independently Predicts Recurrence of Prostate Cancer
Biopharmaceuticals Radiology Oncology
 HSMN NewsFeed - 7 Feb 2007
IRIS Submits 510(k) Application To FDA For Its N.A.D.I.A. Prostate Cancer Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 4 Jan 2007
Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN(R) Clinical Practice Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
New Study Demonstrates That Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Prostate Cancer Recurrence
Diagnostics Urology Oncology
 HSMN NewsFeed - 22 May 2006
Prostate-Specific Membrane Antigen (PSMA) Expression in Neovasculature Associated with Renal Cell Carcinoma is Characterized
Diagnostics Oncology Urology
 HSMN NewsFeed - 8 May 2006
Cytogen Announces FDA Clears IND for CYT-500, a Monoclonal Antibody for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 42

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 42 additional stories matching:
Prostate-Specific Antigen
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.